Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cancer Immunotherapeutic GSK1572932A as Adjuvant Therapy for Patients With MAGE-A3-positive Non-Small Cell Lung Cancer
Brief Summary: The purpose of this clinical trial is to find out how successfully non-small-cell lung cancer patients are able to give an immune response to injections of the immunotherapeutic product GSK1572932A, and to find out more about the safety of this treatment. A course of eight injections will be administered over 21 weeks; including screening for suitability and all tests, the duration of the study for a patient will be 30-35 weeks. During this period various tests will be performed, including physical examinations and blood tests. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.


Options:
A: Arm Label: GSK 249553 Group; Type: EXPERIMENTAL; Interventions: Biological: GSK 249553 vaccine | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: GSK 249553 vaccine; Assigned to Arm(s): GSK 249553 Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group
B: Arm Label: Tecemotide (L-BLP25); Type: EXPERIMENTAL; Interventions: Biological: Tecemotide (L-BLP25), Drug: Single low dose cyclophosphamide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Tecemotide (L-BLP25); Assigned to Arm(s): Tecemotide (L-BLP25) | Intervention Type: DRUG; Name: Single low dose cyclophosphamide; Assigned to Arm(s): Tecemotide (L-BLP25) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Biological: Immunotherapeutic GSK1572932A, Drug: Cisplatin (CDDP), Drug: Vinorelbine | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Biological: Immunotherapeutic GSK1572932A, Drug: Cisplatin (CDDP), Drug: Vinorelbine | Arm Label: Cohort 3; Type: EXPERIMENTAL; Interventions: Biological: Immunotherapeutic GSK1572932A | Arm Label: Cohort 4; Type: EXPERIMENTAL; Interventions: Biological: Immunotherapeutic GSK1572932A, Drug: Cisplatin (CDDP), Drug: Vinorelbine, Procedure: Radiotherapy | Intervention Type: BIOLOGICAL; Name: Immunotherapeutic GSK1572932A; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3, Cohort 4 | Intervention Type: DRUG; Name: Cisplatin (CDDP); Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 4 | Intervention Type: DRUG; Name: Vinorelbine; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 4 | Intervention Type: PROCEDURE; Name: Radiotherapy; Assigned to Arm(s): Cohort 4
D: Arm Label: Investigational Arm; Type: EXPERIMENTAL; Interventions: Biological: Tecemotide, Drug: Single low dose cyclophosphamide, Other: Best Supportive Care (BSC) | Arm Label: Control Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Saline, Other: Best Supportive Care (BSC) | Intervention Type: BIOLOGICAL; Name: Tecemotide; Assigned to Arm(s): Investigational Arm | Intervention Type: DRUG; Name: Single low dose cyclophosphamide; Assigned to Arm(s): Investigational Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Control Arm | Intervention Type: OTHER; Name: Saline; Assigned to Arm(s): Control Arm | Intervention Type: OTHER; Name: Best Supportive Care (BSC); Assigned to Arm(s): Control Arm, Investigational Arm

Answer: C